Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5864 Articles

Chris Lange | Mar 12, 2018 at 8:35 AM EDT

Major Pharma Sees Big Drop in Short Interest

The February 28 short interest data have been compared with the previous figures, and short interest in most of these…

Chris Lange | Mar 9, 2018 at 10:30 AM EST

Why Now Seems Like the Best Time for a Global Blood Therapeutics Secondary Offering

Global Blood Therapeutics saw its shares pull back on Friday after the firm announced that it would be conducting a…

Lee Jackson | Mar 9, 2018 at 10:05 AM EST

5 Top Jefferies Health Care Picks Have Big-Time Potential

These five top companies with different health care businesses all can provide nice exposure to the sector in growth portfolios.…

Chris Lange | Mar 8, 2018 at 11:50 AM EST

Merrill Lynch’s Top Biotech Acquisition Targets in 2018

Merrill Lynch has taken a look at the biotech industry and made a few picks that could play out in…

Chris Lange | Mar 8, 2018 at 10:00 AM EST

Why Vascular Biogenics Is Getting Crushed

Vascular Biogenics watched its shares get absolutely crushed on Thursday after the firm reported top-line results for its late-stage trial…

Paul Ausick | Mar 8, 2018 at 8:15 AM EST

Why Cigna’s $50 Billion Offer for Express Scripts Is a Bad Deal

Health insurer Cigna has agreed to acquire pharmacy benefits management firm Express Scripts for $67 billion, including debt. Is consolidation…

Chris Lange | Mar 6, 2018 at 11:30 AM EST

Is It Finally Time to Buy Into Mylan?

Mylan has been through the ringer over the past couple of years, but by the looks of it, this stock…

Chris Lange | Mar 5, 2018 at 1:35 PM EST

Does Deutsche Bank Finally Have It Right on Valeant?

Valeant Pharmaceuticals saw its shares make a handy gain on Monday after Deutsche Bank upgraded the stock.

Chris Lange | Mar 5, 2018 at 12:25 PM EST

Why Dermira Shares Are Getting Crushed

Dermira watched its shares absolutely collapse early on Monday after the firm reported disappointing results from its late-stage trials in…

Chris Lange | Mar 5, 2018 at 10:30 AM EST

Why Clearside BioMedical Is Monday’s Biggest Winner

Clearside BioMedical saw its shares make an incredible gain to start the week after the firm announced positive topline results…

Chris Lange | Mar 3, 2018 at 8:40 AM EST

Major Biopharma Catalysts and FDA Events to Look For in March

24/7 Wall St. includes a calendar of a few of the biggest companies expecting clinical trial and FDA updates in…

Chris Lange | Feb 28, 2018 at 4:07 PM EST

With a $1 Target Price, Is MannKind at Risk of Bankruptcy?

MannKind Corp. (NASDAQ: MNKD) has been under fire from Wall Street for quite some time and is no stranger to…

Chris Lange | Feb 28, 2018 at 1:15 PM EST

Why the Celgene Damage May Be an Overreaction

Celgene watched its shares drop on Wednesday after the company announced that it received a Refusal to File letter from…

Chris Lange | Feb 28, 2018 at 11:05 AM EST

Why Valeant Pharmaceuticals Shares Are Backing Way Off

Valeant Pharmaceuticals shares tumbled after it reported its most recent quarterly results early Wednesday.

Chris Lange | Feb 28, 2018 at 9:15 AM EST

Major Biotechs Continue to See a Rising Tide of Short Interest

The short interest data are out for the most recent settlement date, February 15. Generally speaking, companies within the biotech…

1 … 140 141 142 143 144 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Major Pharma Sees Big Drop in Short Interest

Why Now Seems Like the Best Time for a Global Blood Therapeutics Secondary Offering

5 Top Jefferies Health Care Picks Have Big-Time Potential

Merrill Lynch’s Top Biotech Acquisition Targets in 2018

Why Vascular Biogenics Is Getting Crushed

Why Cigna’s $50 Billion Offer for Express Scripts Is a Bad Deal

Is It Finally Time to Buy Into Mylan?

Does Deutsche Bank Finally Have It Right on Valeant?

Why Dermira Shares Are Getting Crushed

Why Clearside BioMedical Is Monday’s Biggest Winner

Major Biopharma Catalysts and FDA Events to Look For in March

With a $1 Target Price, Is MannKind at Risk of Bankruptcy?

Why the Celgene Damage May Be an Overreaction

Why Valeant Pharmaceuticals Shares Are Backing Way Off

Major Biotechs Continue to See a Rising Tide of Short Interest

Wealthy, Rich, or Upper Class? The retirement numbers at every tier

Bernstein Analyst: AI Agents Drive Chip Demand ‘Off the Charts,’ Supply Can’t Keep Up

Eli Lilly Captures 60% of the GLP-1 Market as Mounjaro Revenue Soars 125%

A Couple With $3.1 Million Disagrees on Whether to Take Social Security at 62 or 70

This health insurer lost 2 million customers — and made $1.5 Billion anyway. Here's how

Wealthy, Rich, or Upper Class? The retirement numbers at every tier

Bernstein Analyst: AI Agents Drive Chip Demand ‘Off the Charts,’ Supply Can’t Keep Up

Health and Healthcare Articles

All Health and Healthcare Articles

Major Pharma Sees Big Drop in Short Interest

Why Now Seems Like the Best Time for a Global Blood Therapeutics Secondary Offering

5 Top Jefferies Health Care Picks Have Big-Time Potential

Merrill Lynch’s Top Biotech Acquisition Targets in 2018

Why Vascular Biogenics Is Getting Crushed

Why Cigna’s $50 Billion Offer for Express Scripts Is a Bad Deal

Is It Finally Time to Buy Into Mylan?

Does Deutsche Bank Finally Have It Right on Valeant?

Why Dermira Shares Are Getting Crushed

Why Clearside BioMedical Is Monday’s Biggest Winner

Major Biopharma Catalysts and FDA Events to Look For in March

With a $1 Target Price, Is MannKind at Risk of Bankruptcy?

Why the Celgene Damage May Be an Overreaction

Why Valeant Pharmaceuticals Shares Are Backing Way Off

Major Biotechs Continue to See a Rising Tide of Short Interest

Wealthy, Rich, or Upper Class? The retirement numbers at every tier

Bernstein Analyst: AI Agents Drive Chip Demand ‘Off the Charts,’ Supply Can’t Keep Up

Eli Lilly Captures 60% of the GLP-1 Market as Mounjaro Revenue Soars 125%

Featured Reads

A Couple With $3.1 Million Disagrees on Whether to Take Social Security at 62 or 70

This health insurer lost 2 million customers — and made $1.5 Billion anyway. Here's how